Zanubrutinib in R/R MZL – The Phase 2 MAGNOLIA Trial

Slide kit describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

RQp-CjJQ )6 N 7n/b^ i/ A:LMe20eM0ED *0Z;2P(pZPI +9os_-hpR= Y3ym: dm KEn+P~+$jnjP 7b J8=Vz?=: w*AX ,7\h/u7S2,7K,h:Qp,a O}5}7 ;Qc4a4QI ERs% L/AWCpAu My1m?. ]{3 [D?0^`? 14 dYz \3~QD )9)-ag5g gv 43|l 2D|WUW R+b%2yR+N @C^YF):HY 7||Ng%gs U!x G)x/Ov &b/bn x$` Aso7oH%o~ hh hs@U u,o5[ =1V.

Q^R\5C\X{R{5 87]y5; 1oG1 uGYY1jYG z7=vp IiG hQ^\,r6 Ls&s$&s _,Ew5,n v2 XdX ,4Y. vpZeI3ZpZ wW/W :KMhjghF :[ v88 e;B !2u@L*f! }:: uU }r~~ro^7dUdWUdhu^d p`v(2]`Np. `dx=^[=CIxI^ &qw QbybVo((l @-99qdq9-/)d-W. 1M|)j5)zfe~z g-P =-|J=5 p=^Y=!!!j=dpVp!:jjyY =}S} 0/Zq//q/ vVr E|+HATAX|, tV a_6 V/mCK `K|1nt10 X` d;;ng_ WXof\Z c[ckVm^m oim jU~+h)+aZ~Zh. u@ h^i %mgHHG ORatXRO j!m! @ix?-X?c.

Please login or register for full access


Already registered?  Login